Skip to Main Content

Author Details

Keith A Baggerly
The University of Texas MD Anderson Cancer Center
1991
155
56
PMIDPaper TitleJournal TitlePublished Year
36077735Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Cancers (Basel)2022
34117863Methylation-eQTL analysis in cancer research.Bioinformatics2021
33793425Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.JCI Insight2021
33563487Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.Gynecol Oncol2021
34326171Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.J Immunother Cancer2021
34348992Gene Body Methylation of the Lymphocyte-Specific Gene <i>CARD11</i> Results in Its Overexpression and Regulates Cancer mTOR Signaling.Mol Cancer Res2021
32294438Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.Cell Rep2020
32737156Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer.Mol Cancer Ther2020
29428551Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.Eur Urol Focus2019
31112940Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.Acta Haematol2019
31056473Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.EBioMedicine2019
31056348Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.Clin Lymphoma Myeloma Leuk2019
30967390Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.Cancer Prev Res (Phila)2019
30784602Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis.Cell Rep2019
30420565Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.Mol Cancer Ther2019
30474856Refining statistics clarifies leukaemic stem cell genomics.Br J Haematol2019
28827100Carcinoma of the urethra.Hum Pathol2018
37388623Dissecting Pathway Disturbances Using Network Topology and Multi-platform Genomics Data.Stat Biosci2018
35135097Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype.JCO Precis Oncol2018
29889660Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.JCI Insight2018
29861857ADH1B promotes mesothelial clearance and ovarian cancer infiltration.Oncotarget2018
30050129FABP4 as a key determinant of metastatic potential of ovarian cancer.Nat Commun2018
29860375Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach.JAMA Oncol2018
29643062A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research.Clin Cancer Res2018
29776951Experimental Design, Randomization, and Validation.Clin Chem2018
29622464A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.Cancer Cell2018
29032853Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study.Ophthalmology2018
29089331Prevalence of Aflatoxin-Associated <i>TP53R249S</i> Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.Cancer Prev Res (Phila)2018
28710314Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.Clin Cancer Res2017
29872708Immune cell profiling in cancer: molecular approaches to cell-specific identification.NPJ Precis Oncol2017
28106823Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.Int J Mol Sci2017
28102366Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.Sci Rep2017
28350929Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial.JAMA2017
29228548Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.Oncotarget2017
28814667Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.JCI Insight2017
28851898Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.Sci Rep2017
28527672Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.Gynecol Oncol2017
28637689Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.Clin Cancer Res2017
28659338High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.Haematologica2017
28738090Maternal 25(OH)D concentrations â¿¥40 ng/mL associated with 60% lower preterm birth risk among general obstetrical patients at an urban medical center.PLoS One2017
26819345Role of Increased n-acetylaspartate Levels in Cancer.J Natl Cancer Inst2016
26546618Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.Clin Cancer Res2016
26554936Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Carolina March of Dimes 2009-2011 rates.J Steroid Biochem Mol Biol2016
28018013Functional CAR models for large spatially correlated functional datasets.J Am Stat Assoc2016
27612592Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.EBioMedicine2016
27810075Co-localized genomic regulation of miRNA and mRNA via DNA methylation affects survival in multiple tumor types.Cancer Genet2016
26689988NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.Oncotarget2016
26988609Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.Eur Urol2016
27041221A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.Nat Commun2016
27034613Optimized Prediction of Extreme Treatment Outcomes in Ovarian Cancer.Cancer Inform2016
  • 1 - 50 of 155

Recommended Authors

Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Career Start Year 2008
Number of shared co-authors 0
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 18
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 2
Department of Bioinformatics and Clinical Systems
Career Start Year 2006
Number of shared co-authors 3
Department of Food Science and Technology, University of Nebraska-Lincoln
Career Start Year 2006
Number of shared co-authors 2
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 2005
Number of shared co-authors 2
Broad Institute of MIT and Harvard
Career Start Year 2004
Number of shared co-authors 0
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 13
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 7
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 26
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 2
The University of Sydney
Career Start Year 2001
Number of shared co-authors 2
Harvard School of Dental Medicine
Career Start Year 2001
Number of shared co-authors 0
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 8
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 3
University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 1
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 24
The Ohio State University
Career Start Year 1997
Number of shared co-authors 3
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 3
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 1
University of Oslo
Career Start Year 1997
Number of shared co-authors 5
Dana-Farber Cancer Institute & Harvard School of Public Health
Career Start Year 1996
Number of shared co-authors 13
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 3
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
Career Start Year 1996
Number of shared co-authors 1
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 3
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 6
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 6
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 11
Center for Applied Proteomics and Molecular Medicine, George Mason University
Career Start Year 1988
Number of shared co-authors 19
University of California los angeles
Career Start Year 1970
Number of shared co-authors 26

Collaborators

The University of Texas MD Anderson Cancer Center
Co-authored papers 32
Medical College of Georgia
Co-authored papers 30
The University of Texas MD Anderson Cancer Center
Co-authored papers 20
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 20
University of Texas MD Anderson Cancer Center
Co-authored papers 18
The University of Texas MD Anderson Cancer Center
Co-authored papers 12
Co-authored papers 12
Harvard Medical School, Beth Israel Deaconess Medical Center
Co-authored papers 11
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Co-authored papers 8
Johns Hopkins School of Medicine
Co-authored papers 8
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 8
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
University of North Carolina at Chapel Hill
Co-authored papers 7
Co-authored papers 6
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
University of Texas MD Anderson Cancer Center
Co-authored papers 5
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Tokyo University of Science
Co-authored papers 5
Co-authored papers 5
Co-authored papers 5
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Co-authored papers 4
Co-authored papers 4
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Fels Cancer Institute for Personalized Medicine, Temple University School of Medicine
Co-authored papers 4
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
the University of Texas MD Anderson Cancer Center
Co-authored papers 3